No Data
No Data
Genprex Initiated at Buy by HC Wainwright & Co.
Genprex Initiated at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Initiates Coverage On Genprex With Buy Rating, Announces Price Target of $10
Genprex Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/25/2024 216.46% HC Wainwright & Co. → $10 Initiates Coverage On → Buy 01/30/2023 -5.06% Dawson James →
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AUSTIN, Texas — (March 22, 2024) — Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients wi
Genprex Shares Drop 12% on Latest Stock Offering to Get Proceeds of $5.8M
By Sabela Ojea Shares of Genprex on Wednesday dropped after the company agreed to sell common shares and warrants to purchase shares to raise net proceeds of about $5.8 million. In recent trading, s
JAGX and GNPX Among Health Care Movers
No Data